



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,868	08/10/2006	Makoto Kawai	PC26188A	7303
28880	7590	03/11/2009	EXAMINER	
PFIZER INC. PATENT DEPARTMENT, MS8260-1611 GROTON, CT 06340			KUMAR, SHAILENDRA	
			ART UNIT	PAPER NUMBER
			1621	
			NOTIFICATION DATE	DELIVERY MODE
			03/11/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

~IPGSGro@pfizer.com

Office Action Summary	Application No. 10/597,868	Applicant(s) KAWAI ET AL.	
	Examiner SHAIENDRA -. KUMAR	Art Unit 1621	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 August 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15 and 18-20 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-15 and 18-120 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1621

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-2, 6-15 and 18-20, drawn to compounds, composition and method of treatment, when A, B, Z are C, and Cy is non heterocyclic.

Group II, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is C and Cy is non heterocyclic.

Group III, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is non heterocyclic.

Group IV, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is pyrazole.

Group 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is pyran.

Group V, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is pyridine.

Group VI, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is benzoxazole.

Group VII, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is pyradizine.

Group VIII, claim(s) 1, 3-15, and 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is pyrrole.

Group IX, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is indoline.

Group X, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is tetrahydroquinoline.

Art Unit: 1621

Group XI, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is benzimidazole.

Group XII, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is benzothiazole.

Group XIII, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is indazole.

Group IVX, claim(s) 1, 3-15, 18-20, drawn to compounds, composition and method of treatment, when one of A and B is O, Z is N and Cy is triazole.

2. The inventions listed as Groups I - VX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: They are structurally divergent and chemically disparate compounds, thus lacking the same or the corresponding technical feature.

3. In view of the complex nature of the restriction requirement, a written restriction requirement has been made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1621

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA -. KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Daniel Sullivan can be reached on (571)272-0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/SHAILENDRA - KUMAR/
Primary Examiner, Art Unit 1621

S. Kumar
3/5/09